Abstract
The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1265-1266 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 131 |
| Issue number | 12 |
| DOIs |
|
| State | Published - Mar 22 2018 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Fingerprint Dive into the research topics of 'Consensus on MRD in AML?'. Together they form a unique fingerprint.
Cite this
Paietta, E. (2018). Consensus on MRD in AML? Blood, 131(12), 1265-1266. https://doi.org/10.1182/blood-2018-01-828145